La vocation de Roche est de mettre à la disposition du corps médical et des patients des solutions innovantes pour tous et pour chacun. Roche intervient à  tous les niveaux de prise en charge de la maladie pour en diminuer la morbidité et les coûts. L'objectif final est de répondre aux besoins de santé et de garantir la qualité de vie des patients.

Roche Group
Group sales grew 17% in local currencies and 16% in Swiss francs to 11.4 billion Swiss francs
Outlook upgraded: Core Earnings per Share now expected to grow above Group sales growth
Pharmaceuticals Division
Pharmaceutical sales up 20% in local currencies and 18% in Swiss francs, growth three times faster than the global market
Roche Pharma, Genentech and Chugai all achieve double-digit sales growth
All key medicines in oncology, virology, transplantation, osteoporosis and rheumatoid arthritis contribute to strong growth
Approval of Avastin for the treatment of metastatic breast cancer in Europe and of metastatic colorectal cancer in Japan
European approvals for Tarceva in the treatment of metastatic pancreatic cancer and Xeloda in gastric cancer – rollout initiated
Copegus launched in Japan to treat HCV in combination with Pegasys
Positive results for first international phase III trial of Actemra in rheumatoid arthritis
Acquisition of THP and collaboration agreement with Transgene expand technology platform and market potential
Diagnostics Division

Sales grew 6% in local currencies and Swiss francs, outpacing the global in-vitro diagnostics market
Amplicor HPV test and Linear Array HPV genotyping test filed in the US
Acquisitions of 454 Life Sciences and BioVeris will expand market opportunities

02/04/07 Roche acquires THP to expand its therapeutic antibody research 
Roche today announced that it has acquired Therapeutic Human Polyclonals, Inc. (THP) a privately-owned biotechnology company based in California and Germany. With its focus on innovative antibody research, THP will be a valuable addition to Roche’s research organization.
"We are delighted about this acquisition as it builds on our strength in therapeutic antibodies," said Jonathan Knowles, Head of Global Research. "THP and its employees will add cutting-edge capabilities and represent an excellent strategic fit with our own R&D organization. We look forward to welcoming the new members to Roche."
Roche paid 56.5 million US dollars in cash to acquire 100% ownership of THP and plans to fully integrate THP into the Roche Pharma Center of Excellence for Protein Research in Penzberg, Germany.
Modern medical biotechnology uses a wide range of methods to diagnose and treat diseases - from the production of natural products and gene therapy to therapeutic proteins and antibodies. As a company heavily invested in biotechnology and focused on providing added value to patients and healthcare providers, the development of therapeutic proteins and antibodies remains a major emphasis at Roche.

26/02/07 Positive recommendation for Avastin use in advanced or recurrent colorectal cancer in Japan
Priority review process aims to make Avastin available to patients as soon as possible
Roche today announced that Chugai has received a positive recommendation for the use of Avastin (bevacizumab) in patients with advanced or recurrent colorectal cancer. This recommendation was granted by a consultative expert panel for the Japanese Ministry of Health, Labour and Welfare (MHLW). The approval is expected by mid-year.
The Investigational Committee for Usage of Unapproved Drugs (a body established by the MHLW) recommended that an early filing be made for Avastin. Accordingly, Chugai submitted a New Drug Application (NDA) in April 2006. This process enables faster submission of certain medicines with proven efficacy which are approved in the US and/or Europe but are not yet available in Japan.
Roche in the first half of 2006: Outstanding growth
Half-Year Report 2006
Group
• Group sales advance 16% to 20 billion Swiss francs, for a record half-year increase of 3 billion Swiss francs
• Operating profit margin rises 2.4 percentage points to 29.2%
• Net income increases 37% in Swiss francs to 4.5 billion Swiss francs thanks to strong operating performance and higher net financial income
Pharmaceuticals
• Pharmaceutical sales grow 19%, more than three times as fast as the global market
• Cancer medicines deliver 48% growth, reinforcing Roche’s leadership in oncology
• Operating profit margin rises 3.4 percentage points to 32.2%
• Marketing approvals received for Herceptin in early-stage breast cancer and for MabThera in rheumatoid arthritis 
• Mircera filed for the treatment of renal anemia
• Thirteen additional alliances signed, including agreements to co-develop three new research compounds from Chugai
Diagnostics
• Roche Diagnostics posts 4% rise in sales; growth accelerates in second quarter
• As anticipated, investments in ongoing product launches and lower royalty income result in a decline in operating profit
• Renewed Accu-Chek diabetes care portfolio experiencing strong uptake

Outlook for 2006
• Above-market sales growth, with double-digit increases for the Roche Group and the Pharmaceuticals Division
• Target is for core earnings per share to grow ahead of sales

Bâle, le 1er février 2006
Roche en 2005: niveaux records pour le chiffre d?affaires et le bénéfice d'exploitation 
Groupe Roche
•  Le groupe Roche accroît ses ventes de 6 milliards de francs, à un niveau record de plus de 35 milliards de francs
•  La marge d?exploitation est en augmentation de 2,5 points à 25,4%
•  Le bénéfice consolidé atteint pratiquement le niveau de l?année précédente, alors même que le secteur des médicaments en vente libre cédé en 2004 avait généré cette même année un bénéfice de 2,3 milliards de francs
•  Roche s?est vu attribuer une notation financière (credit rating) AA+ par Standard & Poor?s et Aa1 par Moody?s
•  Roche a de nouveau été sélectionnée pour figurer dans les indices Dow Jones axés sur la durabilité •  Dix-neuvième augmentation consécutive du dividende, de 25% à 2,50 francs par action et bon de jouissance Pharma
•  Avec une croissance de 25%, Pharma progresse quatre fois plus vite que le marché mondial •  Nouvelle consolidation de la position de leader du marché des anticancéreux, avec une augmentation des ventes de 42% à 11 milliards de francs
•  Extension considérable des capacités de production de Tamiflu, destinée à couvrir les besoins importants générés par les plans de préparation à une pandémie
•  Résultats positifs d?études cliniques de phase III sur le traitement de la polyarthrite rhumatoïde ainsi que des cancers du sein, du poumon et du pancréas Diagnostics
•  Avec une croissance de 4%, Roche Diagnostics conserve sa place de leader mondial
•  Le bénéfice d?exploitation se situe au niveau record de l?année précédente, tandis que la marge accuse un léger fléchissement
•  Lancement mondial de la nouvelle génération de produits Accu-Chek pour la prise en charge du diabète
Perspectives pour 2006
•  Croissance du chiffre d'affaires supérieure à la croissance du marché, augmentation à deux chiffres pour le groupe Roche et la division Pharma
•  Objectif d?une progression du bénéfice par titre* de l'ordre de la progression des ventes  Taux de croissance en monnaies locales
Marges d'exploitation hors éléments exceptionnels
* Core EPS (earnings per share); croissance du bénéfice par titre

Basel, 9 January 2006 FDA approves first quarterly I.V. injection for postmenopausal osteoporosis in US
New injection brings benefits of Boniva to more women
Roche and GlaxoSmithKline (GSK) announce that the U.S. Food and Drug Administration (FDA) has approved a new, quarterly intravenous (I.V.) injection of the potent and highly effective osteoporosis drug Boniva (ibandronic acid). This is the first ever I.V. injection for the treatment of postmenopausal osteoporosis to be approved by the FDA.
Boniva (known as Bonviva outside the U.S.), is already approved as an effective and well-tolerated1 once-monthly tablet in 33 countries. However, for some women with postmenopausal osteoporosis, oral bisphosphonates are not suitable. These women may be unable to take oral bisphosphonate therapy due to another medical condition or because they can not stay upright for the required length of time.* For these women, Boniva Injection offers a way to gain the proven bone strengthening benefits of bisphosphonate therapy.

Roche poursuit sa forte croissance au troisième trimestre